Latest Tumor markers Stories

New study defuses controversy, shows why individual patient trends are criticalA man's rising PSA (prostate-specific antigen) level over several years "“ which had been seen as a possible warning sign of prostate cancer "“ has recently come under fire as a screening test because it sometimes prompts biopsies that turn out to be normal.A new study, however, shows nearly 70 percent of men who had rising PSA levels and subsequent normal biopsies were eventually diagnosed with prostate...

A new test for prostate cancer that measures levels of prostate specific antigen (PSA) as well as six specific antibodies found in the blood of men with the disease was more sensitive and more specific than the conventional PSA test used today, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.The test, called the A+PSA assay, also reduced the rate of false-positives, tests that indicate the presence of cancer when no disease is actually present, said Gang...

WASHINGTON, May 16, 2011 /PRNewswire/ -- A poster entitled, "Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix versus Degarelix Following Leuprolide Treatment," is being presented at the American Urological Association 2011 meeting by E. David Crawford, MD, head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center in Denver, and lead study investigator. The full manuscript has just been accepted and will be...

A new, promising marker for diagnosing prostate cancer has been discovered by Uppsala researchers with the aid of a unique method developed at the Department of Immunology, Genetics and Pathology. The study, being published this week in the journal Proceedings of the National Academy of Sciences, PNAS, can lead to more reliable diagnoses and fewer unnecessary operations.The PSA marker used for diagnosing prostate cancer today has been criticized for false positive responses, leading to...

NEW YORK, April 19, 2011 /PRNewswire/ -- According to a research from Northwestern Medicine, a new PSA (prostate-specific antigen) screening test for prostate cancer can more accurately identify aggressive forms of the disease and substantially reduce false positives, as compared to the two methods currently available. "This discovery is especially significant for men over 50 whose PSA levels put them in a 'gray zone,' where a biopsy may not be needed," said Dr. David B. Samadi, a prostate...

The dog may be man's best friend but even so it comes as a surprise that the two species share a common tumor marker.  This finding comes from a joint study between scientists of the Vetmeduni Vienna and the MedUni Wien, headed by Erika Jensen-Jarolim.  The researchers looked for similarities in breast cancer of dogs and women, focusing on the tumor marker CEA (carcinoembryonic antigen).  They uncovered a molecule, the CEA receptor, that turned out to be essentially identical in the...

NEW YORK, April 14, 2011 /PRNewswire/ -- Dr. David Samadi, Vice Chairman, Department Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City, expressed concern today regarding the conclusions of a study published this month in the British Medical Journal (BMJ). Following a group of 9,000 men for 20 years; 1,500 of whom were screened for prostate cancer every three years, with the rest functioning as a control, the study set out to...

Women with ovarian cancer who have the BRCA2 gene mutation are more likely to survive the malignancy than women with the BRCA1 mutation, or women without either mutation.In results presented at the AACR 102nd Annual Meeting 2011, held April 2-6, Kelly Bolton, a fellow at the National Cancer Institute, said the findings describe the effect of these mutations in ovarian cancer survival."There was some previous evidence that women with ovarian cancer who have mutations in the BRCA genes...

RICHMOND, Va., March 1, 2011 /PRNewswire/ -- Wako Diagnostics, a division of Wako Chemicals USA, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the uTASWako i30 instrument with alpha-fetoprotein L3 (AFP-L3) and des-gamma-carboxy prothrombin (DCP) in vitro diagnostic (IVD) tests in the USA. The AFP-L3 and DCP assays are intended for use by healthcare professionals as an aid in the risk assessment of patients with chronic liver disease for...

Screening for PSA velocity leads to many unnecessary biopsies and should be removed from screening guidelinesResearchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time "” known as PSA velocity "” is a poor predictor of prostate cancer and may lead to many unnecessary biopsies. The new study of more than 5,000 men was published online February 24 in the Journal of the National Cancer Institute. Andrew Vickers, PhD, Associate Attending Research...